Literature DB >> 2137890

Serum protein binding characteristics of cyproterone acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man.

Q G Li1, M Hümpel.   

Abstract

Protein binding characteristics including percentage of total binding, total binding capacity (pmol/mg protein), degree of specific binding, competition with dihydrotestosterone (DHT) and estradiol (E2) binding sites and dissociation constants (Kd) of low and high affinity binding sites were investigated for the progestins cyproterone acetate (CPA), gestodene (G), norethisterone (NET) and levonorgestrel (LN) in serum or plasma pools from man and four laboratory animal species (rat, rabbit, dog and monkey). Serum pools from animals were constructed from samples obtained either prior to or 1 day after pretreatment with ethinyl estradiol (EE2) (5 micrograms/kg/day for 7 days). Human plasma pools differed by SHBG levels (normal/induced). All serum pools were characterized by protein content and distribution. Equilibrium dialysis or dextran-coated charcoal (DCC) methods were used to separate bound and free steroids labelled with tritium. All progestins were highly (greater than 80%) bound to proteins in all undiluted samples. Total binding capacity was highest in rat and lowest in monkey. Human plasma showed a capacity of 1.5-2.1 microgram steroid/ml. In man, monkey and rabbit LN and G were specifically bound to the same degree as DHT, whereas NET binding was 50% lower. Specific binding of CPA to dog serum was 2-3 times higher than for other steroids. Two (high and low affinity) binding sites were found for LN, G and NET in man, monkey and rabbit and in dog for LN. Kd values for high affinity binding ranged from 3.5 (G in man) to 23 (NET in man) x 10(-9)M. Kd values of low affinity binding varied from 0.5 (CPA in dog) to 4 (NET in man) x 10(-6)M. E2 and DHT competition experiments confirmed the concept of SHBG as a carrier protein of 19-nor-progestins and DHT and its occurrence in man, monkey and rabbit. A sex hormone binding protein (SBP) in the dog seems to be responsible for the relatively high specific binding of CPA. SHBG is inducible by means of EE2 in man and monkey, but not in rabbit. EE2 may induce SBP in the dog. Comparison of in vitro Kds (high affinity binding) and in vivo metabolic clearance rates showed the same rankings for LN, G and NET in man, monkey and rabbit.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137890     DOI: 10.1016/0022-4731(90)90291-y

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  6 in total

1.  Specific binding sites for corticosterone in isolated cells and plasma membrane from rat liver.

Authors:  M Trueba; I Ibarrola; K Ogiza; A Marino; J M Macarulla
Journal:  J Membr Biol       Date:  1991-03       Impact factor: 1.843

2.  Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey.

Authors:  Q G Li; M Hümpel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Oct-Dec       Impact factor: 2.441

Review 3.  Desexing Dogs: A Review of the Current Literature.

Authors:  Silvan R Urfer; Matt Kaeberlein
Journal:  Animals (Basel)       Date:  2019-12-05       Impact factor: 2.752

4.  Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.

Authors:  Lisa H Xie; Qigui Li; Jing Zhang; Peter J Weina
Journal:  Malar J       Date:  2009-05-26       Impact factor: 2.979

5.  Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Brian Cicali; Karthik Lingineni; Rodrigo Cristofoletti; Thomas Wendl; Joachim Hoechel; Herbert Wiesinger; Ayyappa Chaturvedula; Valvanera Vozmediano; Stephan Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-13

6.  In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel.

Authors:  Owain Roberts; Hannah Kinvig; Andrew Owen; Mohammed Lamorde; Marco Siccardi; Kimberly K Scarsi
Journal:  HIV Med       Date:  2021-07-30       Impact factor: 3.094

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.